BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26085442)

  • 21. Calculating life? Duelling discourses in interdisciplinary systems biology.
    Calvert J; Fujimura JH
    Stud Hist Philos Biol Biomed Sci; 2011 Jun; 42(2):155-63. PubMed ID: 21486653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Designing synthetic biology.
    Agapakis CM
    ACS Synth Biol; 2014 Mar; 3(3):121-8. PubMed ID: 24156739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthetic Biology: Old and New Dilemmas-The Case of Artificial Life.
    Kolisis N; Kolisis F
    BioTech (Basel); 2021 Jul; 10(3):. PubMed ID: 35822770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthetic Biology in the FDA Realm: Toward Productive Oversight Assessment.
    Fatehi L; Hall RF
    Food Drug Law J; 2015; 70(2):339-69, iii-iv. PubMed ID: 26302603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new approach to an old problem: synthetic biology tools for human disease and metabolism.
    Burrill DR; Boyle PM; Silver PA
    Cold Spring Harb Symp Quant Biol; 2011; 76():145-54. PubMed ID: 22169233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. (Re-)Designing Nature? An Overview and Outlook on the Ethical and Societal Challenges in Synthetic Biology.
    Braun M; Fernau S; Dabrock P
    Adv Biosyst; 2019 Jun; 3(6):e1800326. PubMed ID: 32648715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progress in governance of converging technologies integrated from the nanoscale.
    Roco MC
    Ann N Y Acad Sci; 2006 Dec; 1093():1-23. PubMed ID: 17312249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Left to their own devices: Post-ELSI, ethical equipment and the International Genetically Engineered Machine (iGEM) Competition.
    Balmer AS; Bulpin KJ
    Biosocieties; 2013 Sep; 8(3):311-335. PubMed ID: 24159360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Making Common Sense of Vaccines: An Example of Discussing the Recombinant Attenuated
    Dankel DJ; Roland KL; Fisher M; Brenneman K; Delgado A; Santander J; Baek CH; Clark-Curtiss J; Strand R; Curtiss R
    Nanoethics; 2014; 8(2):179-185. PubMed ID: 25152775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Societal Risk Evaluation Scheme (SRES): Scenario-Based Multi-Criteria Evaluation of Synthetic Biology Applications.
    Cummings CL; Kuzma J
    PLoS One; 2017; 12(1):e0168564. PubMed ID: 28052080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthetic biology between challenges and risks: suggestions for a model of governance and a regulatory framework, based on fundamental rights.
    Colussi IA
    Rev Derecho Genoma Hum; 2013; (38):185-214. PubMed ID: 24340832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Professionalization as a governance strategy for synthetic biology.
    Weir L; Selgelid MJ
    Syst Synth Biol; 2009 Dec; 3(1-4):91-7. PubMed ID: 19816804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole-of-society approach for public health policymaking: a case study of polycentric governance from Quebec, Canada.
    Addy NA; Poirier A; Blouin C; Drager N; Dubé L
    Ann N Y Acad Sci; 2014 Dec; 1331():216-229. PubMed ID: 25118135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The whack-a-mole governance challenge for AI-enabled synthetic biology: literature review and emerging frameworks.
    Undheim TA
    Front Bioeng Biotechnol; 2024; 12():1359768. PubMed ID: 38481570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Translational synthetic biology.
    Singh M; Vaidya A
    Syst Synth Biol; 2015 Dec; 9(4):191-195. PubMed ID: 28392851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What is good governance in the context of drug policy?
    Singleton N; Rubin J
    Int J Drug Policy; 2014 Sep; 25(5):935-41. PubMed ID: 24768218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthetic biology and its alternatives. Descartes, Kant and the idea of engineering biological machines.
    Kogge W; Richter M
    Stud Hist Philos Biol Biomed Sci; 2013 Jun; 44(2):181-9. PubMed ID: 23623436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. It is important to note that RWD will never replace the more traditional and more robust RCT data; however, the emerging trend is to incorporate data that are more generalizable. Introduction.
    Mullins CD; Sanchez RJ
    J Manag Care Pharm; 2011; 17(9 Suppl A):S03-4. PubMed ID: 22074667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Working towards a national health information system in Australia.
    Bomba B; Cooper J; Miller M
    Medinfo; 1995; 8 Pt 2():1633. PubMed ID: 8591519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Knowledge-making distinctions in synthetic biology.
    O'Malley MA; Powell A; Davies JF; Calvert J
    Bioessays; 2008 Jan; 30(1):57-65. PubMed ID: 18081015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.